IL17A and psoriasis: Recently, a new psoriasis treatment consisting of an anti-IL-17/anti-IL-17-receptor antibody has been developed with promising effects [39].However, there are some concerns about the side effects of the anti-IL17-receptor antibody, which approximately 70–80% of the test subjects experienced during the course of a 12 week clinical trial.